BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 10378692)

  • 1. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
    Lüscher B; Larsson LG
    Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K; Anand G; Yin X; Grove L; Prochownik EV
    Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the Myc and Max interaction specificity with lambda repressor-HLH domain fusions.
    Marchetti A; Abril-Marti M; Illi B; Cesareni G; Nasi S
    J Mol Biol; 1995 May; 248(3):541-50. PubMed ID: 7752223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and properties of a Myc derivative that efficiently homodimerizes.
    Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
    Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
    Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
    J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of Max: role of basic, helix-loop-helix/leucine zipper domains in DNA binding, dimerization and regulation of Myc-mediated transcriptional activation.
    Reddy CD; Dasgupta P; Saikumar P; Dudek H; Rauscher FJ; Reddy EP
    Oncogene; 1992 Oct; 7(10):2085-92. PubMed ID: 1408152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
    Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
    Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of sequences responsible for the differential regulation of Myc function by delta Max and Max.
    Västrik I; Mäkelä TP; Koskinen PJ; Alitalo K
    Oncogene; 1995 Aug; 11(3):553-60. PubMed ID: 7630640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells.
    Larsson LG; Bahram F; Burkhardt H; Lüscher B
    Oncogene; 1997 Aug; 15(6):737-48. PubMed ID: 9264414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X; Giap C; Lazo JS; Prochownik EV
    Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral mutations enhance the Max binding properties of the vMyc b-HLH-LZ domain.
    Crouch DH; Fisher F; La Rocca SA; Goding CR; Gillespie DA
    Nucleic Acids Res; 2005; 33(16):5235-42. PubMed ID: 16166655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both the helix-loop-helix and the leucine zipper motifs of c-Myc contribute to its dimerization specificity with Max.
    Davis LJ; Halazonetis TD
    Oncogene; 1993 Jan; 8(1):125-32. PubMed ID: 8423990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Myc does not require max for transcriptional activity in PC-12 cells.
    Ribon V; Leff T; Saltiel AR
    Mol Cell Neurosci; 1994 Jun; 5(3):277-82. PubMed ID: 8087425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taking myc to the max.
    Turner R
    Nat Struct Biol; 2003 Mar; 10(3):157. PubMed ID: 12605219
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolutionary relationships and functional conservation among vertebrate Max-associated proteins: the zebra fish homolog of Mxi1.
    Schreiber-Agus N; Chin L; Chen K; Torres R; Thomson CT; Sacchettini JC; DePinho RA
    Oncogene; 1994 Nov; 9(11):3167-77. PubMed ID: 7936639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
    Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
    Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
    Bousset K; Henriksson M; Lüscher-Firzlaff JM; Litchfield DW; Lüscher B
    Oncogene; 1993 Dec; 8(12):3211-20. PubMed ID: 8247525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
    Lavigne P; Crump MP; Gagné SM; Hodges RS; Kay CM; Sykes BD
    J Mol Biol; 1998 Aug; 281(1):165-81. PubMed ID: 9680483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
    Soucek L; Jucker R; Panacchia L; Ricordy R; Tatò F; Nasi S
    Cancer Res; 2002 Jun; 62(12):3507-10. PubMed ID: 12067996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex.
    Wu S; Peña A; Korcz A; Soprano DR; Soprano KJ
    Oncogene; 1996 Feb; 12(3):621-9. PubMed ID: 8637719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.